UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

ý Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2012

¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

COMMISSION FILE NO. 1-11602

APPLIED NANOTECH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

TEXAS	76-0273345
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

3006 Longhorn Blvd., Suite 107
Austin, Texas	78758
(Address of principal executive offices)	(Zip Code)

(512) 339-5020

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

T Yes £ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files.

T Yes £ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of “accelerated filer”, “large accelerated filer”, and “smaller reporting company” in rule 12b-2 of the Act.

Large Accelerated Filer  o    Accelerated Filer  o

Non-accelerated Filer  o    Smaller Reporting Company  þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

£ Yes T No

As of July 31, 2012, the registrant had 119,171,607 shares of common stock, par value $.001 per share, issued and outstanding.

APPLIED NANOTECH HOLDINGS, INC.

INDEX

Part I.  Financial Information			Page
	Item 1.  Financial Statements
		Consolidated Balance Sheets--June 30, 2012 and December 31, 2011	3
		Consolidated Statements of Operations --Three Months and Six Months Ended June 30, 2012 and 2011	4
		Consolidated Statements of Cash Flows --Six Months Ended June 30, 2012 and 2011	5
		Notes  to Consolidated Financial Statements	6
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		8
	Item 3. Quantitative and Qualitative Disclosures about Market Risk		11
	Item 4. Controls and Procedures		11
Part II.  Other Information
	Item 6.  Exhibits		12
Signatures			13

2

PART I.  FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS

APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

ASSETS	(Unaudited) June 30, 2012			December 31, 2011
Current assets:
Cash and cash equivalents	$	690,994		$	3,071,783
Accounts receivable – net of allowance for doubtful accounts		706,881			839,863
Prepaid expenses and other current assets		751,096			153,021
Total current assets		2,148,971			4,064,667
Property and equipment, net		327,466			303,055
Other assets		28,591			28,745
Total assets	$	2,505,028		$	4,396,467
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	746,125		$	324,333
Convertible notes payable		1,591,532			1,486,510
Obligations under capital lease		58,379			40,701
Accrued liabilities		477,437			379,675
Deferred revenue		–			200,000
Total current liabilities		2,873,473			2,431,219
Obligations under capital lease, long-term		37,677			48,559
Convertible notes payable, long-term		457,895			–
Total liabilities		3,369,045			2,479,778
Commitments and contingencies		–			–
Stockholders' equity (deficit):
Preferred stock, $1.00 par value, 2,000,000 shares authorized; No shares issued and outstanding		–			–
Common stock, $.00l par value, 160,000,000 shares authorized, 119,137,920 and 118,915,698 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively		119,138			118,916
Additional paid-in capital		115,031,102			114,654,026
Accumulated deficit		(116,014,257	)		(112,856,253	)
Total stockholders’ equity (deficit)		(864,017	)		1,916,689
Total liabilities and stockholders’ equity (deficit)	$	2,505,028		$	4,396,467

See notes to consolidated financial statements.

3

APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2012			2011			2012			2011
Revenues
Government contracts	$	370,378		$	1,081,544		$	786,544		$	2,332,636
Contract research		84,142			294,809			151,354			843,599
License fees and royalties		601,596			261,700			778,896			262,840
Product sales		65,618			5,518			134,488			20,338
Other		8,217			18,963			55,805			140,102
Total revenues		1,129,951			1,662,534			1,907,087			3,599,515
Research and development		1,377,005			1,391,906			2,730,271			2,993,640
Selling, general and administrative expenses		1,206,428			638,141			2,148,432			1,455,696
Operating costs and expenses		2,583,433			2,030,047			4,878,703			4,449,336
Loss from operations		(1,453,482	)		(367,513	)		(2,971,616	)		(849,821	)
Other income (expense), net
Interest expense		(98,052	)		(78,140	)		(187,963	)		(210,571	)
Interest income		729			12,534			1,575			13,476
Loss from continuing operations before taxes		(1,550,805	)		(433,119	)		(3,158,004	)		(1,046,916	)
Provision for taxes		–			–			–			–
Net loss	$	(1,550,805	)	$	(433,119	)	$	(3,158,004	)	$	(1,046,916	)
Earnings (loss) per share
Basic and Diluted	$	(0.01	)	$	(0.00	)	$	(0.03	)	$	(0.01	)
Weighted average shares outstanding
Basic		119,137,920			118,756,832			119,099,859			114,758,368
Diluted		119,137,920			118,756,832			119,099,859			114,758,368

See notes to consolidated financial statements.

4

APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For  the Six Months Ended June 30,
	2012			2011
Cash flows from operating activities:
Net loss	$	(3,158,004	)	$	(1,046,916	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		54,554			30,601
Amortization of discount on debt		112,917			138,239
Stock based compensation expense		167,298			338,041
Changes in assets and liabilities:
Accounts receivable, trade		132,982			(447,942	)
Prepaid expenses and other assets		(597,921	)		(42,853	)
Accounts payable and accrued liabilities		579,554			(195,867	)
Deferred revenue		(200,000	)		186,200
Total adjustments		249,384			6,419
Net cash used in operating activities		(2,908,620	)		(1,040,497	)
Cash flows from investing activities:
Purchases of property and equipment		(50,398	)		(34,404	)
Net cash used in investing activities		(50,398	)		(34,404	)
Cash flows from financing activities:
Repayment of capital leases		(21,771	)		(12,061	)
Proceeds from long-term debt		600,000			–
Proceeds from stock issuance, net of costs		–			2,551,751
Net cash provided by financing activities		578,229			2,539,690
Net increase (decrease) in cash and cash equivalents		(2,380,789	)		1,464,789
Cash and cash equivalents, beginning of period		3,071,783			2,732,570
Cash and cash equivalents, end of period	$	690,994		$	4,197,359

See notes to consolidated financial statements.

5

APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.       Basis of Presentation

The consolidated financial statements for the three and six month periods ended June 30, 2012 and 2011 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2012 and 2011, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2011, has been derived from the audited consolidated balance sheet as of that date.

Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as filed with the U.S. Securities and Exchange Commission.

The results of operations for the three and six month periods ended June 30, 2012, are not necessarily indicative of the results to be expected for the full year.

2.       Supplemental Cash Flow Information

Cash paid for interest for the six months ended June 30, 2012 and 2011, was $7,069 and $1,783, respectively. During the six months ended June 30, 2012 and 2011, the Company had non-cash transactions related to share based payments described in greater detail in Note 5 and non-cash transactions related to the conversion of notes payable and related accrued interest into common stock that are described in greater detail in Note 3. In addition, $60,000 of accounts payable were converted into common stock in each of 2012 and 2011, respectively. The Company also had a capital lease transaction in the amount of $28,567 in the six months ended June 30, 2012.

3.       Notes Payable and Long-Term Debt

We issued convertible notes payable in 2009 and 2010. These notes bear interest at a rate of 8% and are due in 2012. The notes and resulting accrued interest are convertible into shares of our common stock at rates of $0.20 to $0.25 per share. The face amount of the notes due was $2,146,000 and we valued the conversion rights at $647,250, which was recorded as a discount at the time of issuance. This discount is being amortized to interest expense over the term of the notes. $216,000 of these notes were issued to officers and directors of the Company. As of June 30, 2012, a total of $526,000 of these notes have been converted to common stock, leaving a remaining principal balance as of that date of $1,620,000. During the six months ended June 30, 2011, a total of $326,000 of principal and related accrued interest of $31,394 was converted into 1,764,144 shares of common stock. During the six months ended June 30, 2012, an additional $600,000 of convertible notes payable, bearing interest at 8%, were issued. These notes and the related accrued interest are convertible into common stock at a rate of $0.16 per share and due in January, 2014. The value of the conversion rights were valued at $150,000, which was recorded as a discount and is being amortized over the term of the notes.

4.       Stockholders’ Equity

During the six months ended June 30, 2011, we issued 6,578,948 restricted shares of common stock and received proceeds of $2.5 million in an exempt offering under Regulation D of the Securities Act of 1933, and 200,454 shares for total proceeds of $51,751 in connection with the exercise of options by former employees. We also issued 157,895 shares of restricted common stock in payment of accounts payable in the amount of $60,000 during the same period, as well as 103,722 shares in connection with restricted stock payments to employees.

During the six months ended June 30, 2012, we issued 222,222 shares of common stock in payment of accounts payable in the amount of $60,000.

6

APPLIED NANOTECH HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

5.       Share-Based Payments

We use the fair value method to account for stock based compensation. We recorded $167,298 and $338,041 in compensation expense in the periods ended June 30, 2012 and 2011, respectively, related to options and restricted stock issued under our stock-based incentive compensation plans. This includes expense related to both options issued and committed, as well as unissued restricted stock in the current year, and options issued in prior years for which the requisite service period for those options includes the current year. The fair value of these options was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. For options issued in 2012, the same approximate assumptions were used.

6.       Contingencies

Litigation

The Company is a defendant in minor lawsuits described in greater detail in its 2011 Annual Report on Form 10-K. The Company expects any potential eventual payment to have no material effect on the financial statements.

7.       Subsequent Events

During the period from July 1, 2012 through July 31, 2012, the Company issued additional notes payable in the amount of $231,700 under the same terms as described in Note 3. The Company also paid an additional refundable deposit in connection with a potential acquisition in the amount of $370,000 in July 2012.

7

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements.

FORWARD-LOOKING STATEMENTS

This Form 10-Q contains certain forward-looking statements that we believe are within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by such acts. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements, including the statements under "Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding our strategy, future operations, future expectations or future estimates, financial position and objectives of management. Those statements in this Form 10-Q containing the words "believes," "anticipates," "plans," "expects" and similar expressions constitute forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on our current expectations and are subject to a number of risks, uncertainties and assumptions relating to our operations, results of operations, competitive factors, shifts in market demand and other risks and uncertainties.

Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate and actual results may differ from those indicated by the forward-looking statements included in this Form 10-Q. In light of the significant uncertainties inherent in the forward-looking statements included in this Form 10-Q, you should not consider the inclusion of such information as a representation by us or anyone else that we will achieve such results. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.

Six months ended June 30, 2012 and 2011

OVERVIEW

We are primarily a nanotechnology company engaged in the development of technologies, based principally on our intellectual property. We generate revenues by performing research services, licensing our technology, and selling products based on our technology. During all periods presented, our primary revenues were earned as a result of reimbursed research expenditures and licensing of our technology. As more fully discussed in our Annual Report on Form 10-K for the year ended December 31, 2011, we expect to incur significant additional research and development expenses in 2012 to further develop and commercialize our technology. We are focused on commercializing our technology and obtaining sufficient revenue to cover our ongoing expenditures.

OUTLOOK

We expect our present cash balances, which were approximately $700,000 at June 30, 2012, when combined with expected revenue sources and money being raised, to enable us to operate through the end of 2012. However, our cash on hand is only adequate to allow us to operate through the end of August, 2012. This has been reduced from the end of September 2012 time period identified in the 2012 first quarter 10Q as a result of the accelerated spending on commercialization also identified in our 2012 first quarter 10Q, including the costs related to a potential acquisition. We also expect to sign additional revenue generating contracts which will continue to extend this time period. If we do not receive the expected revenue sources as quickly as anticipated, we may be required to cut back on our commercialization activities, or raise additional funding beyond the amount currently planned.

We have a plan to achieve profitability in 2012, and that plan anticipated a loss in the first half, which was expected to be offset by profits for the balance of the year. Since developing this plan, we have accelerated spending on commercialization activities, including pursuing an acquisition opportunity. This will make it difficult for us to achieve profitability this year. We also anticipate hiring additional sales resources in August 2012 that will further increase our costs, but are necessary to build revenues. A critical component of our plan is the receipt of additional revenues. These revenues must come from a variety of sources, including research revenues, license fees – either in the form of an upfront payment, or from ongoing royalties as a result of product sales by our licensees, and product sales by us. In addition, we expect to continue our accelerated spending on commercialization, including costs related to our potential acquisition.

8

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (cont.)

At the present time, there can be no assurance that we will achieve our plan for profitability in 2012, or that expected revenue sources will all occur as planned. It is not possible for us to achieve profitability without license fees or royalties at our present level of activity. In order to achieve profitability solely based on research revenues, our research revenue would have to more than double from our expected level for 2012, and the majority of the revenue would have to come from non-governmental sources. The mix of revenues received could also cause the revenues required to reach break-even to increase. If revenue producing projects require unanticipated expenses, or heavier than anticipated use of outside services and materials, we may be unable to achieve profitability at the expected level of revenues.  We believe that we have the ability to continue to obtain funding, if necessary, to enable us to continue operations until we reach profitability.  

Our plan is based on current development plans, current operating plans, the current regulatory environment, historical experience in the development of electronic products and general economic conditions. Changes could occur which would cause certain assumptions on which this plan is based to be no longer valid. If adequate funds are not available from operations, or other sources of financing, we may have to eliminate, or reduce substantially, expenditures for research and development, testing and production of its products, or obtain funds through arrangements with other entities that may require us to relinquish rights to certain of our technologies or products. Such results could materially and adversely affect us.

RECENT DEVELOPMENTS

In the second quarter of 2012, we formed a subsidiary, EZDiagnostiX, Inc., to focus on commercialization of our sensor technology and signed a non-binding letter of intent to acquire an existing company for the subsidiary. We are currently in the due diligence period and have provided refundable deposits related to the acquisition totaling $995,000. Of this $625,000 was paid in June 2012, and $370,000 in July 2012. The acquisition target had sales of approximately $12.5 million in 2011. Also in the second quarter of 2012, we began raising $2.0 million through the issuance of convertible notes payable that are due in 2014 and convertible into common stock at a price of $0.16 per share.

We received approximately $1.2 million of additional government contracts in July 2012.

RECENT ACCOUNTING PRONOUNCEMENTS

There are no recent accounting pronouncements that we have not implemented that are expected to have a material impact on our financial statements.

FINANCIAL CONDITION AND LIQUIDITY

Our cash position decreased during the period from approximately $3.1 million at December 31, 2011 to approximately $700,000 at June 30, 2012. This decrease in cash is primarily the result of cash used in operating activities.

Our net cash used in operating activities increased from approximately $1.0 million in the 2011 Period to approximately $2.9 million in the 2012 Period. This is primarily the result of operating factors discussed below in the “Results of Operations”.

Cash used in investing activities in both periods was insignificant and related to the purchase of capital equipment. We expect cash used in investing activities to remain at relatively insignificant levels for the balance of 2012.

We had cash provided by financing activities in both periods. In 2012 we had cash generated from the issuance of notes payable in the amount of $600,000 and in 2011 we received approximately $2.5 million in proceeds from the issuance of common stock . There were insignificant amounts of cash used in financing activities in both periods related to payments on capital leases.

Historically, the principal source of our liquidity has been funds received from exempt offerings of common stock. We are currently raising funds to accelerate our commercialization activities and to facilitate a potential acquisition. While we expect to be able to obtain any funds needed for operations, there can be no assurance that any of these financing alternatives can be arranged on commercially acceptable terms. We believe that our success in reaching profitability will be dependent on our patent portfolio and upon the viability of products using our technology and their acceptance in the marketplace, as well as our ability to obtain additional debt or equity financings in the future, if needed.

9

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (cont.)

We expect to continue to incur substantial expenses for research, development and commercialization activities. Further, we believe that certain products that may be developed by potential licensees of our technology may not be available for commercial sale or routine use for a period of one to two years. Others are expected to be available in 2012. While we would likely receive initial license payments, ongoing royalty streams related to some licenses may not be available until potential licensees have introduced products using our technology. Therefore, it is possible that the commercialization of our existing and proposed products may require additional capital in excess of our current funding. We did, however, have a plan to operate profitably in 2012 based on the receipt of research funding, license agreements, product sales, and other revenues. However, our accelerated spending on commercialization activities, including a potential acquisition, will make it difficult for us to achieve profitability in 2012. Achievement of at least break-even would enable us to continue our research without seeking additional financing in the future.

Because the timing and receipt of revenues from product sales, or license and royalty agreements will be tied to the achievement of certain product development, testing and marketing objectives, which cannot be predicted with certainty, there may be substantial fluctuations in our results of operations. If revenues do not increase as rapidly as anticipated, or if product development and testing require more funding than anticipated, we may be required to curtail our operations or seek additional financing from other sources at some point in the future. The combined effect of the foregoing may prevent us from achieving sustained profitability for an extended period of time.

RESULTS OF OPERATIONS

Our net loss for the second quarter ended June 30, 2012 was approximately $1.6 million as compared with a net loss of approximately $400,000 for the same period last year. Our net loss of approximately $3.2 million for the six months ended June 30, 2012 was increased from the loss of approximately $1.0 for the six months ended June 30, 2011. This increased loss was the result of reasons set forth below.

Our revenues for the quarter ended June 30, 2012 totaled approximately $1.1 million compared to approximately $1.7 million for the same quarter of 2011. For the six-month period ended June 30, 2012 (the “2012 Period”), our revenues were approximately $1.9 million as compared with approximately $3.6 million for the six-month period ended June 30, 2011 (the “2011 Period). The largest source of revenues in the 2012 Period was from contract research – approximately $938,000, of which approximately $787,000 of which was from government sources. This is a significant decrease from the 2011 Period and was the result of two main reasons. First, during 2011, we had a Phase 3 commercialization contract which resulted in $1.2 million in revenue in the 2011 Period. There was no such contract in 2012. In addition, we had significant research revenue from the NE Gas association in 2011, almost $500,000, whereas we had only approximately $50,000 in revenue from the same source in 2012. In addition, certain research contracts that we expected to receive were delayed in 2012. We received an additional $1.2 million in government research contracts in July 2012.

Our license fees and royalties increased significantly in 2012. Of the total of approximately $779,000 in royalty revenue, $500,000 was from the remainder of the YHCC license signed in 2011. The balance of approximately $279,000 was from Yonex. The 2011 amount was substantially all from Yonex. We also had a significant increase in our product sales from 2011 to 2012, which is the result of our increased focus in this area. We expect product sales to continue to grow throughout the remainder of the year.

We have a research revenue backlog of approximately $2.9 million as of the date of this filing, including the $1.2 million in contracts received in July, as compared to our backlog of approximately $1.1 million as of June 30, 2011, and $2.3 million at December 31, 2011. We have several quotes in process and we expect to land additional research contract and we expect our research revenue to increase during the third and fourth quarters of 2012. Our ability to perform continued research, or fulfill our backlog, will not require additional personnel. We do not anticipate hiring any additional people for research purposes for the balance of the year, unless we receive significant new revenues.

10

ITEM 2:  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (cont.)

At the present stage of our development, significant conclusions cannot be drawn by comparing revenues from period to period; however, we would expect the quarterly revenue for the balance of 2012 to increase above the level of the first two quarters. Our plan calls for targeted revenues of $8.8 million for 2012. We are currently behind our revenue plan and may not be able to make up the shortfall, particularly in the research area; however, our plan anticipated increased revenues in the third and fourth quarters. Our business strategy is built on commercializing our technology through product sales and developing a royalty stream from licensing our intellectual property. To supplement this, we also seek funding from both governmental and private sources to help fund our research. Until we are able to develop a steady revenue stream from royalties, or product sales, our revenues will tend to fluctuate greatly from quarter to quarter. Our private research funding tends to come in large amounts at sporadic times.

We incurred research and development expenses of approximately $2.7 million in the 2012 Period, which was down from the amount of approximately $3.0 million incurred in the 2011 Period. This decrease in research expenses is a direct result of the decreased research revenue in 2012. The decrease in expense was less than the decrease in research revenue since some of the expenses are fixed and a portion of the labor previously devoted to funded projects is now devoted to unfunded commercialization development activities. Significant new revenue producing research programs beyond those already identified could, however, cause research and development expenditures to increase.

Our selling, general, and administrative expenses increased from approximately $1.5 million in 2011 to $2.1 million in 2012. The overwhelming majority of this increase, approximately $550,000, is the result of the formation of our sensor subsidiary and due diligence activities related to the planned acquisition for the subsidiary. The balance of the increase is primarily related to increased selling expenses related to other areas of our business.

Our interest income is insignificant in both periods. Our interest income results from the investment of excess funds in short term interest bearing instruments, primarily certificates of deposit, commercial paper, and money market funds. We expect our interest income to remain at insignificant levels for the balance of 2012. Our interest expense, which is primarily the result of our convertible notes payable, decreased in the 2012 Period. This interest expense includes both the stated interest rate on the debt and the amortization of the discount associated with the notes. The interest expense decreased because a portion of the notes were converted in 2011.We would expect our interest expense to remain at similar levels for the third and fourth quarters of 2012. We expect the notes due in the third quarter of 2012 to be converted or extended when they become due.

ITEM 3. Quantitative and Qualitative disclosures about market risk

We do not use any derivative financial instruments for hedging, speculative, or trading purposes. Our exposure to market risk is currently immaterial.

ITEM 4. Controls and Procedures

Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of the end of the period covered by this report (the "Evaluation Date"). Based upon this evaluation, our principal executive officer and principal financial officer concluded as of the Evaluation Date that our disclosure controls and procedures were effective such that the material information required to be included in our Securities and Exchange Commission ("SEC") reports is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms relating to the Company, including, our consolidated subsidiaries, and was made known to them by others within those entities, particularly during the period when this report was being prepared.

In addition, there were no significant changes in our internal controls over financial reporting or in other factors that could significantly affect these controls subsequent to the Evaluation Date. We have not identified any material weaknesses in our internal controls, and therefore, no corrective actions were taken.

11

PART II. OTHER INFORMATION

ITEM 6.  EXHIBITS

Exhibits: See Index to Exhibits on page 14 for a descriptive response to this item.

12

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	APPLIED NANOTECH HOLDINGS, INC. (Registrant)
Date:     August 7, 2012	/s/ Douglas P. Baker
	Douglas P. Baker Chief Executive Officer, Chief Financial Officer (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

13

INDEX TO EXHIBITS

The following documents are filed as part of this Report:

Exhibit
11	Computation of (Loss) Per Common Share
31.1	Rule 13a-14(a)/15d-14(a) Certificate of Douglas P. Baker
32.1	Section 1350 Certificate of Douglas P. Baker

14